Technavio’s market research report on CAR-T cell therapy for liver and lung cancer provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules, which fall under CAR T-cell therapy for liver cancer and lung cancer.
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors, and CAR T-cells. They are engineered receptors that graft an arbitrary specificity onto an immune effector cell (T-cell). CAR T-cell therapy uses the individual’s own cells and “re-engineers” them to fight cancer. It is a very complex treatment process.
According to a senior analyst at Technavio for oncology, “In the current pipeline for CAR T-cell therapy for liver and lung cancer, 50% of the pipeline candidates account for liver cancer, 30% account for lung cancer, and 20% of the pipeline candidates account for liver and lung cancer.”
The report provides an in-depth analysis of CAR-T cell therapy for liver and lung cancer market, including therapeutic assessment based on RoA (intrahepatic and intravenous, intratumoral, intrahepatic, intravenous, and unspecified) and therapeutic assessment by target (AFP, MUC1, GPC3, CEA, and undisclosed).
In the intratumoral route of drug administration, the drug is directly injected into the tumor. Around 20% of the pipeline therapeutics of CAR T-cell therapy for liver and lung cancer are being evaluated by this route. Around 10% of the candidates are being evaluated by the intravenous route, and around 10% are being evaluated by intrahepatic and intravenous route. Around 50% of pipeline CAR T-cell therapeutics have been put in an unspecified category.
